In Silico Approach in Predicting Bioactivity, ADMET, and Therapeutic Targets of Dexamethasone
DOI:
https://doi.org/10.30872/jtpc.v9i3.316Keywords:
Dexamethasone, Target Prediction, PASS Online, ADMET, In SilicoAbstract
Dexamethasone is a synthetic glucocorticoid widely used for its potent anti-inflammatory and immunosuppressive effects; however, its broad biological activity and potential adverse effects necessitate a comprehensive pharmacological evaluation. This study aimed to investigate the bioactivity profile, potential molecular targets, and ADMET properties of dexamethasone using an integrated in silico approach. Bioactivity prediction was performed using PASS Online, target identification was conducted via SwissTargetPrediction, and pharmacokinetic–toxicological profiling was evaluated using the pkCSM platform. The results revealed high probabilities for anti-inflammatory, antiallergic, and immunosuppressive activities, confirming the established therapeutic roles of dexamethasone. Multiple nuclear receptors, including the glucocorticoid, mineralocorticoid, androgen, and progesterone receptors, were identified as primary targets, providing mechanistic insight into both therapeutic effects and endocrine-related adverse outcomes. Additional targets related to inflammatory signaling, metabolic regulation, and G-protein–coupled receptors suggested broader pharmacological interactions. ADMET predictions indicated high intestinal absorption, moderate distribution, limited central nervous system penetration, manageable metabolic interactions, and low predicted toxicity risks.
Downloads
References
[1] M. A. Islam, "Dexamethasone: A comprehensive review of pharmacological properties and clinical applications in the post-pandemic era," J. Clin. Pharm. Ther., vol. 2023, no. 1, pp. 102–115, Jan. 2023.
[2] R. Tanaka and S. Hirose, "In silico target fishing of synthetic glucocorticoids: Identification of novel off-target interactions," Bioinform. Biol. Insights, vol. 17, pp. 1–14, Mar. 2023.
[3] L. Zhang et al., "Molecular docking and dynamic simulation of dexamethasone with non-canonical steroid receptors," Int. J. Mol. Sci., vol. 24, no. 4, p. 3512, Feb. 2023.
[4] K. S. Kumar and P. V. Ramana, "Advanced ADMET profiling of corticosteroids using deep learning architectures," Comput. Biol. Med., vol. 158, p. 106821, May 2023.
[5] J. H. Smith and A. R. Taylor, "Clinical safety of high-dose dexamethasone: A systematic review of 2023 evidence," Lancet Rheumatol., vol. 5, no. 6, pp. e324–e335, Jun. 2023.
[6] M. Rossi et al., "Prediction of dexamethasone-induced metabolic disturbances through integrative cheminformatics," Toxicol. Appl. Pharmacol., vol. 468, p. 116520, Aug. 2023.
[7] N. Ahmed and S. Sultana, "Machine learning-based bioactivity prediction for repurposed anti-inflammatory drugs," Front. Pharmacol., vol. 14, p. 1123456, Sep. 2023.
[8] G. B. Watson, "Evolution of glucocorticoid receptor modeling: From docking to molecular dynamics," Trends Pharmacol. Sci., vol. 44, no. 10, pp. 680–694, Oct. 2023.
[9] C. L. Huang, "Systematic evaluation of ADMET properties of dexamethasone derivatives using modern in silico platforms," Drug Metab. Dispos., vol. 51, no. 11, pp. 1420–1432, Nov. 2023.
[10] P. Gupta and R. Sharma, "Bioinformatics approaches in understanding glucocorticoid resistance mechanisms," Brief. Bioinform., vol. 25, no. 1, p. bbad450, Jan. 2024.
[11] S. Lee and K. Park, "The role of dexamethasone in severe inflammatory responses: A 2024 updated molecular perspective," Crit. Care, vol. 28, no. 1, p. 45, Feb. 2024.
[12] D. Miller et al., "SwissADME and ProTox-II: Comparative analysis of corticosteroid toxicity profiles," J. Cheminformatics, vol. 16, no. 2, pp. 12–25, Mar. 2024.
[13] Y. Chen, "Virtual screening and target identification of glucocorticoids in autoimmune disorders," J. Mol. Graph. Model., vol. 128, p. 108710, Apr. 2024.
[14] A. Moreno and J. Lopez, "Rational drug use of dexamethasone: Personalized medicine through in silico modeling," Pharmaceutics, vol. 16, no. 5, p. 612, May 2024.
[15] T. J. O’Sullivan, "Evaluating the pharmacokinetic landscape of dexamethasone in 2024," Clin. Pharmacokinet., vol. 63, no. 6, pp. 745–760, Jun. 2024.
[16] H. Wang et al., "Deep learning models for predicting blood-brain barrier penetration of synthetic steroids," Bioinformatics, vol. 40, no. 7, p. btae412, Jul. 2024.
[17] R. K. Singh, "In silico exploration of dexamethasone as an adjunct therapy in oncology," Mol. Divers., vol. 28, no. 4, pp. 1580–1595, Aug. 2024.
[18] B. Zhao and L. Liu, "Global trends in computational toxicology for anti-inflammatory agents," Environ. Toxicol. Pharmacol., vol. 110, p. 104522, Sep. 2024.
[19] F. G. Santos, "The impact of computational biology on drug safety evaluation: Dexamethasone case study," Biomedicines, vol. 12, no. 10, p. 2210, Oct. 2024.
[20] M. Kim and J. Choi, "Integration of transcriptomics and in silico docking to map glucocorticoid pathways," Nucleic Acids Res., vol. 52, no. D1, pp. D120–D130, Jan. 2025.
[21] J. P. Doe, "Predictive modeling of corticosteroid-induced osteoporosis: An in silico approach," Bone Rep., vol. 22, p. 101850, Feb. 2025.
[22] A. R. White, "Next-generation ADMET analysis: Moving beyond the classical parameters," Nat. Rev. Drug Discov., vol. 24, no. 3, pp. 185–186, Mar. 2025.
[23] L. Peterson, "Dexamethasone bioactivity: New insights from AI-driven ligand-protein interaction studies," J. Med. Chem., vol. 68, no. 4, pp. 2900–2915, Apr. 2025.
[24] K. Yamane, "Rational optimization of glucocorticoid therapy using integrative bioinformatics," NPJ Syst. Biol. Appl., vol. 11, no. 1, p. 15, May 2025.
[25] E. Braun, "Computational toxicology of endocrine disruptors and synthetic hormones," Toxicol. Sci., vol. 195, no. 1, pp. 40–55, Jun. 2025.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Fendy Prasetyawan, M Wahyu Ariawan, Yuneka Saristiana, Lisa Savitri (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
